Price Target of $1.78
SeeThruEquity Initiates Coverage on Zecotek Photonics Inc. (TSXV: ZMS) with Price Target of $1.78
V.ZMS | 47 minutes ago
NEW YORK, NY / ACCESSWIRE / February 5, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has initiated coverage of Zecotek Photonics Inc. (TSXV: ZMS) with a Price Target of $1.78.
Founded in 2004, ZMS a developer of leading-edge photonics technologies and products for commercial and research applications. The company possesses a rich portfolio of more than 50 U.S. and international patents across its three subsidiaries - Zecotek Imaging Systems Pte Ltd.; Zecotek Display Systems Pte Ltd.; and Zecotek Laser Systems Pte Ltd. Zecotek has commercial and research partnership agreements with various organizations including Hamamatsu of Japan, CERN in Switzerland, Beijing Opto-Electronics Technology Co. Ltd. in China, the University of Washington in the U.S., NuCare Medical Systems and National NanoFab Center (both based in South Korea).
The report is available here: ZMS.V Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will also be available on these platforms. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.
Additional highlights from the report are as follows:
Patented technologies provide significant competitive advantage
Zecotek possesses a large portfolio of over 50 patent‐protected photonics technologies in technically challenging and high growth areas. The company's core focus over the past few years has been the development of its Imaging Systems division through three key patented technologies - LFS scintillation crystals; MAPD Solid‐state photo detectors; and Integrated Detector Modules for PET/MRI scanners. Zecotek's LFS scintillation crystals and MAPD solid‐state photo detectors offer significant cost and performance advantages over existing imaging technologies in the fields of high energy physics and medical diagnostics. Zecotek has developed a new compact and cost-effective MAPD photo-detector for low light detection that will phase out the bulky and expensive PMT's (photo multiplier tubes) presently used in different imaging applications such as PET, Gamma cameras and high-energy nuclear physics. We believe Zecotek is the only company with possession of all three of the key elements necessary for PET/MRI scanner construction.
Commercialization of existing technologies through partnerships
Zecotek is transitioning from an R&D to a revenue generating company by actively pursuing commercialization of its patented technologies through strategic partnerships. In July 2013, Zecotek inked a strategic commercial partnership with Hamamatsu Photonics of Japan, which has so far placed orders worth $2.0mn for Zecotek's LFS scintillation crystals. ZMS is also in a multi-year research partnership with CERN (The European Organization for Nuclear Research), which has successfully used Zecotek's MAPD detectors and LFS crystals in a variety of experiments. We believe CERN's usage of Zecotek's products validates their superior performance, and aid in their path towards continued commercialization.
Enters 3D printing with disruptive technology
In a major strategic move, Zecotek announced entry into the fast growing 3D printing market in early 2014, offering enormous growth potential for the company. The company's subsidiary Zecotek Display Systems Pte. Ltd. is working with LT-Pyrkal of Yerevan, Armenia, to design a unique 3D printer, which will offer technical and commercial competitive advantages to existing 3D printers. Zecotek is also developing a 3D printing interface which offers significant design, cost, and time advantages when used with Zecotek's glasses free, auto-stereoscopic, multi-view, HD 3D display. Development of the printer is moving at a fast pace and ahead of schedule, with commercial launch expected in 2015.
Please review important disclosures on our website at www.seethruequity.com.
About Zecotek Photonics Inc.
Zecotek Photonics Inc. is a developer of next-generation photonics technologies and products for commercial and research applications. Founded in 2004 and headquartered in Vancouver, B.C., Canada, Zecotek operates through three subsidiary companies incorporated in Singapore - Zecotek Imaging Systems Pte Ltd. (ZIS); Zecotek Display Systems Pte Ltd. (ZDS); and Zecotek Laser Systems Pte Ltd. (ZLS). These subsidiary companies are incorporated in Singapore and owned by the holding company Zecotek Photonics Singapore Pte.Ltd. The company holds a rich portfolio of more than 50 U.S. and international patents across its three subsidiaries. ZMS trades on the TSX Venture Exchange under the symbol "ZMS" and on the Frankfurt Stock Exchange under the symbol "W1I."
For more information, please visit www.zecotek.com.
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.
For more information visit www.seethruequity.com.
February 5, 2015 - 9:01 AM EST
Was haltet Ihr davon ??????????????